Xtandi 40 MG capsule 120S
Ended Awarded Last action
- Contract number
- SPE2DR26FCRL6
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $12,766
Award facts
- Contract value 100% obligated
- $12,766.02 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $12,766.02 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-count units). This firm fixed-price delivery order, issued on November 28, 2025, with an ultimate completion date of December 1, 2025, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The award was funded by the Defense Logistics Agency and represents a routine pharmaceutical supply transaction supporting Department of Defense medical operations.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated SPE2DR, which was awarded on November 13, 2025, with a $500 million ceiling and completion date of December 31, 2036. The PPV-G GEN V represents a broader $30.3 billion acquisition strategy designed to provide comprehensive pharmaceutical sourcing, including branded and generic prescription drugs, biologics, and medical consumables, to support military healthcare facilities worldwide. DMS Pharmaceutical Group's established performance across numerous delivery orders demonstrates its capability to fulfill the specialized pharmaceutical requirements of the federal military medical system.
Quick answers
Who was awarded contract SPE2DR26FCRL6?
SPE2DR26FCRL6 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 28, 2025.
How much is contract SPE2DR26FCRL6 worth?
The government has obligated $12,766 on SPE2DR26FCRL6.
Is contract SPE2DR26FCRL6 an order under another contract?
Yes. SPE2DR26FCRL6 is a delivery order under SPE2DR25D9168, an indefinite delivery contract.
Was contract SPE2DR26FCRL6 competed?
The extent of competition for SPE2DR26FCRL6 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award